SERI Lugano: ParaCel Riboflavin Selected by FDA for Epi-on Cross-Linking for Keratoconus
The Switzerland Eye Research Institute has announced that the breakthrough transepithelial riboflavin formulation known as ParaCel, and based on the research of its CEO and Founder Roberto Pinelli, MD, has been selected among many others by the FDA for an epithelium-on corneal collagen cross-linking protocol for patients with progressive keratoconus, according to a press release.
All of the intellectual property rights to produce, market and distribute ParaCel have been acquired by AVEDRO, Inc. Waltham. Mass. in 2011. Avedro reached the agreement with FDA in order for many patients and practices in the US to offer a new procedure designed to eliminate the need to remove the epithelium, explained Avedro’s chief medical officer Rajesh K. Rajpal, MD, in the release.
“ParaCel has been formulated to softly penetrate the corneal epithelium without the need to remove it. The higher concentration of riboflavin and proprietary formulation allow for the fastest penetration and diffusion into the corneal stroma. The osmotic property of this distinctive riboflavin solution is the key to the efficacy and safety of this treatment. I am happy to know that the molecule I conceived and then released to AVEDRO was chosen by such an outstanding institution as the FDA”, said Dr. Roberto Pinelli.
ABOUT SWITZERLAND EYE RESEARCH INSTITUTE
Founded by Dr. Pinelli in 2013, the Switzerland Eye Research Institute (SERI Lugano) is a private center based in Lugano, Switzerland, specializing in the diagnosis, study and treatment of visual defects and eye diseases. Dr. Pinelli has performed more than 20,000 procedures over the last 20 years. His expertise in the treatment of keratoconus led to his personal technique for a transepithelial osmotic accelerated cross-linking for keratoconus with the use of ParaCel riboflavin and to the introduction of cross-linking in the refractive procedures performed at the Institute on a regular basis.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
PSE20.4.2018 17:15 | pressemeddelelse
PSE: APM Forum 2018 Focus on Digitalisation for the Process Industries
APERTA20.4.2018 16:03 | pressemeddelelse
Aperta Provides Electronic Funds Transfer (EFT) in Cayman Islands
SECO-SPA20.4.2018 15:41 | pressemeddelelse
FII Tech Growth Invests in SECO
SCHLUMBERGER-LIMITED20.4.2018 13:07 | pressemeddelelse
Schlumberger Announces First-Quarter 2018 Results
MA-BIOGEN20.4.2018 12:32 | pressemeddelelse
Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases
AZ-VERSUM-MATERIALS19.4.2018 22:17 | pressemeddelelse
Versum Materials Celebrates the Grand Opening of Its Research and Development Facility in Hometown, PA
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum